Abbott stock rises on AFib device data buzz as traders weigh FDA overhang
Abbott shares climbed 1.5% to $112.68 Tuesday, outperforming a flat healthcare sector as new atrial fibrillation device data drew investor attention. The company reported 93.9% complete closure at 45 days in its VERITAS study and 84.2% one-year freedom-from-recurrence with its Volt PFA system. Investors remain alert to fallout from Abbott’s recent diabetes sensor recall. Trading volume was near typical levels.